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Paul A. Hoffmeister,1 Sangeeta R. Hingorani,1,2 Barry E. Storer,1 K. Scott Baker,1,2
Jean E. Sanders1,2A retrospective study was conducted to determine risk factors for the development of hypertension (HTN)
and to describe the prevalence among long-term survivors of pediatric hematopoietic cell transplant (HCT).
Records of 689 pediatric patients who survived 5 years or more after HCT, from 1969 to 2004, were
reviewed for development of HTN. In children, HTN was defined as either a systolic or diastolic pressure
$95th percentile according to age, sex, and height. In adults, HTN was defined as systolic pressures
$140 mmHg and/or diastolic pressures $90 mmHg in nondiabetic adults and systolic pressures $130
and/or diastolic pressures$80 in diabetic adults. Multivariate Cox regression models were used to estimate
the hazard ratio (HR) of risk factors associated with HTN. All patients included were off immunosuppressive
therapy. Patients had been treated with total body irradiation (TBI) (n 5 482, 70%) or non-TBI regimens
(n 5 207, 30%) followed by autologous (n 5 87), related (n 5 484), or unrelated donor HCT (n 5 118).
Median follow-up was 16 (range: 5-36) years. HTN developed in 120 patients with a 30-year cumulative
incidence of 36%. Risk factors associated with HTN were acute kidney injury (AKI; doubling of baseline cre-
atinine by day 100 after HCT) (HR 5 2.5; 95% confidence interval (CI) 1.7-3.7, P\.0001), TBI in the pre-
parative regimen (HR 5 2.1; 95% CI 1.3-3.3, P 5 .001), donor type (autologous HR 5 2.4; 95% CI 1.3-4.4
and unrelated donor HR 5 1.8; 95% CI 1.0-3.2, P 5 .01), obesity (HR 5 4.0; 95% CI 2.3-6.8, P\.0001), di-
abetes (HR5 6.7; 95% CI 3.9-11.0, P\0.0001), and history of growth hormone therapy (HR5 1.6; 95% CI
1.0-2.5, P5.05). Patients with a positive history of hepatitis C infection were less likely to develop HTN (HR
5 0.5; 95% CI 0.3-0.9, P 5 .009). Prevalence of HTN was 15% overall and among survivors 11-17 years and
18-39 years old, the prevalence was 10% and 14% or triple and double that of the general U.S. population,
respectively. Pediatric HCT survivors are more likely to develop HTN than the general population and
should be monitored for HTN throughout adulthood.
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Survivors of pediatric hematopoietic cell trans-
plant (HCT) are at risk for developing a variety of
late complications. As long-term survival increases,
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pediatric HCT has been reported to occur in up to
12% of patients, little is known about the prevalence
and risk factors for development of HTN in long-
term survivors [1-4].
It is estimated that 29% of the adult U.S. popula-
tion has HTN or are taking antihypertensive medica-
tion [5]. HTN is more prevalent in African Americans
than Whites and more prevalent in men than women
[5]. A number of factors are associated with increased
blood pressure including older age, obesity, insulin
resistance, physical inactivity, excess alcohol consump-
tion, stress, and dietary factors [6]. Other factors in-
clude kidney disease, sleep apnea, nicotine, and
endocrine disorders [7].
The development of HTN in pediatric HCT pa-
tients may be multifactorial. Potential nephrotoxins
that can lead to kidney disease include chemotherapy
agents such as platinum compounds, carmustine, and515
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dominal irradiation, antifungal and antiviral agents,
aminoglycoside antiobiotics, and immunosuppressive
therapy (calcineurin inhibitors) to prevent or treat
graft-versus-host disease (GVHD) [8]. Acute kidney
injury (AKI) may occur in up to 53% of HCT patients
[3,9-12]. TBI may cause radiation nephropathy that
can present more than 6 months after HCT [13]. Pedi-
atric HCT survivors are also at risk for developing the
metabolic syndrome, of which HTN is 1 of the con-
tributing conditions [14-16]. Furthermore, pediatric
and adult HCT patients have an increased risk for
developing type 2 diabetes mellitus, which may lead
to nephropathy and hypertension [17,18].
The individual and cumulative affect of these
potential insults on the development of HTN is
unknown. The purpose of this study is to identify
risk factors associated with the development of HTN
and to describe the prevalence of HTN in a large pop-
ulation of long-term pediatric HCT survivors.PATIENTS AND METHODS
Patient Selection
Between 1969, and January 1, 2004, 2016 consecu-
tive children\18 years of age received an HCT at the
Fred Hutchinson Cancer Research Center (FHCRC),
Seattle, WA. The records of all 789 patients who sur-
vived $5 years after transplantation were reviewed.
Excluded from the analysis were 91 patients who had
relapsed, were receiving immunosuppression for
chronic GVHD (cGVHD), or had no follow-up blood
pressure readings, 4 patients who did not consent to
follow-up, and 5 patients with pretransplant condi-
tions that may have predisposed them to developing
HTN after transplant including polycystic kidney dis-
ease (n 5 2), idiopathic HTN (n 5 2), and congenital
aortic coarctation (n5 1). The remaining 689 patients
or their responsible guardians consented to follow-up
under Protocol 999.2 and the data was reviewed under
Protocol 1782 approved by the FHCRC institutional
review board.Transplant Preparative Regimen, Source of
Stem Cells, and Supportive Care
Treatment prior to referral forHCTvariedwith the
referring institution. Transplant preparative regimens
included either chemotherapy or chemoradiotherapy
as previously described [19-25]. Most chemotherapy-
only regimens utilized cyclophosphamide (Cy) 50 mg/
kg/day for 4 days for aplastic anemia (AA) patients or
Cy 50 mg/kg/day for 4 days combined with busulfan
(Bu) 4 mg/kg/day for 4 days for patients with a hemato-
logic malignancy and some patients with nonmalignant
hematologic disorders [19-23]. Most TBI regimensincludedCy60mg/kg/day for 2 days.TBIwas delivered
from dual opposing cobalt-60 sources at a dose rate in
air of 5-8 cGy/min as either 9.2-10.0Gysingle-exposure
TBI or fractionated TBI with exposures of 2.0-2.75 Gy
for 6 to 7 consecutive days or hyperfractionated
exposures of 1.2 Gy 2-3 times daily for 4 consecutive
days [19,21,24,25].Nonmyeloablative (NMA) regimens
consisted of fludarabine (Flu) and low-dose (2-6 Gy)
TBI [26]. The kidneys were not shielded during TBI.
Autologous transplant recipients received either
bone marrow (BM) or peripheral blood stem cells
(PBSCs). Allogeneic transplant recipients received
either BM, PBSC, or umbilical cord blood (UCB)
stem cells harvested from related or unrelated donors
[27,28]. All allogeneic transplant recipients received
prophylaxis for acute GVHD (aGVHD) depending
on the type of donor and protocol in use at time of
HCT, and generally included either methotrexate
(MTX) or MTX and a calcineurin inhibitor [29-31].
aGVHD and cGVHD were diagnosed, graded, and
treated as previously described [32-35]. Hepatitis C
virus (HCV) screening began in 1991 as previously
described [36].
Follow-up
All patients had an evaluation for engraftment and
GVHD at 80 to 100 days after transplant. Patients re-
turned to the FHCRC for long-term follow-up at 1
year and electively thereafter. Follow-up after 1 year
consisted of annual contact with referring physicians
from 1969 to 1990. From 1991 to the present, ques-
tionnaires were mailed annually to patients and their
primary medical provider. Information gathered in-
cluded new medical conditions, medications, blood
pressure, and results of blood testing (complete blood
count and chemistries). Study data were collected
through April 15, 2009. Of the 689 patients studied,
612 were alive. Follow-up data within the past 4 years
was available for 90% of the patients.
Study Data
Data were obtained from the FHCRC clinical
information database, pretransplant medical records,
transplant flow-sheets, and long-term follow-up
records. Records were reviewed for development of
HTN.
In patients \18 years old, HTN was defined as
either a systolic or diastolic pressure $95th percentile
according to age, sex, and height [37]. In patients$18
years of age, HTN was defined as systolic pressures
$140 mmHg and/or diastolic pressures $90 mmHg.
Patients with diabetes were considered to be hyperten-
sive with systolic pressures $130 mmHg and/or dia-
stolic pressures $80 mmHg [38].
The onset of HTNwas defined as the first of 2 con-
secutive blood pressure readings showing HTN or the
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died of secondarymalignancies, who received immuno-
suppression for non-GVHD conditions (organ trans-
plant, pulmonary disease, or autoimmune disease), or
received antihypertensive medications for nonhyper-
tensive conditions (cardiac disease, cardiomyopathy,
portal hypertension, edema, or headaches), only blood
pressure readings prior to these events were considered.
However, patients were classified as hypertensive if they
developed breakthrough HTN while on antihyperten-
sive medications for nonhypertensive conditions.
Body mass index (BMI, kg/m2) was calculated
based on patient height and weight at diagnosis of
HTN or most recent measurements in nonhyperten-
sive patients. Obesity was defined as a BMI$95th per-
centile based on age and sex in patients\18 years old
and a BMI $30 in patients $18 years old [39,40].
Weight loss was defined as a decrease in weight of 5
kg or more in adults or a decrease of 10 or more
BMI percentile-points in children. AKI was defined
as a doubling of baseline serum creatinine within the
first 100 days after transplant [11]. Sinusoidal obstruc-
tion syndrome (SOS) (previously veno-occlusive dis-
ease) was defined according to established criterion
[41]. Glomerular filtration rate (GFR) was estimated
for children using the equations of Schwartz et al.
and the Modification of Diet in Renal Disease equa-
tion for adults [42,43]. HCV infection status was based
on available medical records.Statistical Methods
The prognostic factors considered for the develop-
ment of HTN included baseline patient and transplant
characteristics: sex, race/ethnicity, family history of
HTN (defined as any relative within 2 degrees of sep-
aration), single kidney, abdominal irradiation, cranial
irradiation, pretransplant nephrotoxic chemotherapy
agents, age at transplantation, diagnosis at transplanta-
tion, TBI (yes/no), donor type (autologous, related,
unrelated), degree of HLA-antigen mismatching
between donor and recipient, AKI, SOS, cyclosporine
(CsA)/tacrolimus for aGVHD prophylaxis, aGVHD
grade (0-I versus II-IV), cGVHD (defined as clinical
extensive), CsA/tacrolimus, prednisone, or mycophe-
nolate mofetil (MMF) for cGVHD therapy, duration
of cGVHD therapy, smoking history, and HCV infec-
tion. Time-dependent risk factors considered included
obesity, diabetes, growth hormone deficiency, and
growth hormone therapy. For the purpose of analysis,
transplant diagnoses were categorized into 9 groups:
acute lymphoblastic leukemia (ALL), acute myeloge-
nous leukemia (AML), chronic myelogenous leukemia
(CML), myelodysplastic syndrome (MDS), non-
Hodgkin lymphoma (NHL), neuroblastoma, aplastic
anemia (AA), primary immunodeficiencies and red
blood cell disorders, and all other diagnoses. Redblood cell disorders included thalassemia, sickle cell
anemia, and red cell aplasia. Cox regression analysis
was used to evaluate univariate andmultivariate associ-
ations of pretransplantation and time-dependent risk
factors with the development of HTN. The cumula-
tive incidence of HTN after transplant was estimated
by standard methods [44]. Statistical significance was
set at P-value\.05 and the stability of the estimates re-
flected by 95% confidence intervals. Statistical data
were analyzed using SAS software (SAS Institute,
Cary, NC). The point prevalence of HTN among sur-
viving leukemia patients was calculated using the for-
mula (hypertensive patients/total population at risk)
as of April 15, 2009 [45]. Descriptive data were ana-
lyzed using SPSS software (SPSS Inc., Chicago, IL).
Descriptive statistics were described as mean and
range.RESULTS
Patient Population
The patient and transplant characteristics of the
study population and hypertensive cases are presented
in Table 1. Among 689 patients, 120 (17%) developed
HTN during a median follow-up period of 16 (5-36)
years. There were no significant differences between
patients with and without HTN with regard to family
history of HTN, non-White race, donor type, and
aGVHD or cGVHD. However, among evaluable
patients, AKI was higher in 47% (51/109) of patients
with HTN than 32% without HTN (176/547) (P 5
.003).
Among the 120 patients who developed HTN, 6
(5%) patients had experienced renal complications
prior to transplantation (2 acute tubular necrosis, 2
severe tumor lysis syndrome, 1 leukemic infiltration
of the kidney and transient renal failure, and 1 mem-
braneous glomerulonephropathy). Four of the 6
patients required hemodialysis (data not shown).
Characteristics of patients at onset of HTN are
presented in Table 2. At onset of HTN, 17% of
patients were obese, 16% had diabetes, 20% were in-
fected with HCV, and 13% were smokers. Chronic
kidney disease (GFR\90 mL/min/1.73 m2) was pres-
ent in 23 (32%) of 72 evaluable patients at the time of
diagnosis of HTN. Nine (39%) of the 23 patients with
chronic kidney disease had a history of AKI (data not
shown). At the onset of HTN, 10 patients had renal
imaging performed of whom 8 were normal, 1 had
a solitary kidney with multiple cysts, and 1 had bilat-
eral increased echogenecity, kidney stones, and hydro-
nephrosis. Three patients had sleep apnea (data not
shown). Thirteen children had been on growth hor-
mone therapy for a median of 2.7 (1.7-4.7) years prior
to developing HTN.
Table 1. Patient and Transplant Characteristics of Study
Population and Hypertensive Cases
Total Hypertensive
Number of patients 689 120
Gender
Female 284 (41%) 45 (37%)
Male 405 (59%) 75 (63%)
Race/Ethnicity
Non-Hispanic White 573 (83%) 102 (85%)
Other race/ethnicity 116 (27%) 18 (15%)
Family history of HTN
Yes 96 (14%) 19 (16%)
No 209 (30%) 30 (25%)
Unknown 384 (56%) 71 (59%)
Pre-HCTabdominal irradiation (yes) 22 (3%) 4 (3%)
Pre-HCT single kidney (yes) 13 (2%) 4 (3%)
Pre-HCT cranial irradiation (yes) 131 (19%) 31 (26%)
Diagnosis at transplant
ALL 204 (30%) 45 (38%)
AML 157 (23%) 22 (18%)
Aplastic anemia 106 (15%) 19 (16%)
CML 55 (8%) 12 (10%)
Neuroblastoma 39 (6%) 6 (5%)
PID/RCD 33 (5%) 1 (<1%)
MDS 33 (5%) 7 (6%)
Non-Hodgkin’s lymphoma 16 (2%) 3 (3%)
Other* 46 (7%) 5 (4%)
Age at transplant—years (range) 9.2 (0.3-18.0) 10.4 (1.0-18.0)
Donor type at first HCT
Related 484 (70%) 89 (74%)
Unrelated 118 (17%) 18 (15%)
Autologus 87 (13%) 13 (11%)
Source of stem cells at first HCT
Bone marrow 619 (90%) 111 (93%)
Peripheral blood 62 (9%) 8 (7%)
Cord blood 8 (1%) 1 (<1%)
Transplant preparative regimen
Single fraction 10 Gy TBI 79 (11%) 28 (23%)
Fractionated 12-15.75 Gy TBI 356 (52%) 64 (53%)
Low-dose 2-6 Gy TBI 10 (1%) –
Non-TBI containing regimens
Cyclophosphamide 89 (13%) 18 (15%)
Busulfan and cyclophosphamide 80 (12%) 4 (3%)
Other 29 (4%) 2 (2%)
Two transplants 46 (7%) 4 (3%)
Acute kidney injury
Yes 227 (33%) 51 (43%)
No 429 (62%) 58 (48%)
Unknown 33 (5%) 11 (9%)
Acute GVHD grades
0-I 375 (54%) 69 (58%)
II-IV 314 (46%) 51 (43%)
Chronic GVHD (yes) 225 (33%) 44 (37%)
Survivors 612 (89%) 104 (87%)
Years alive post-HCT (range) 17.4 (5.0-36.6) 18.4 (5.1-36.1)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CML, chronic myelogenous leukemia; GVHD, graft-versus-
host disease; HCT, hematopoietic cell transplantation; HTN, hyperten-
sion; MDS, myelodysplastic syndrome; PID, primary immunodeficiency
disease; RCD, red blood cell disorder; TBI, total body irradiation.
*Other diagnosis include: Fanconi’s anemia (n5 12), juvenile myelomo-
nocytic leukemia (n5 8), Hodgkin disease (n5 8), brain tumors (n5 5),
and other rare diseases (n 5 13).
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when they developed HTN, 45% of adult patients had
a decreased GFR versus 8% of children, and 21% of
adults had diabetes versus 3% of children. Obesity
was similar in children and adults (18% versus 16%,
respectively). Isolated diastolic HTN was found in30% of adults and only 13% of children, whereas
isolated systolic HTN was more common in children
(41%) than adults (25%).HTN Treatment, Complications, and Survival
Among the 120 patients who developed HTN, 78
were started on antihypertensive medications, 38 did
not receivemedications, and 4developed breakthrough
HTNwhile on antihypertensive medications for other
reasons. Among the 78 patients started on antihyper-
tensive medications, 41 started therapy within 1 year
of developing HTN, 32 started therapy a median of
2.2 (1.0-9.9) years later, and the start date was unknown
for 5 patients. Of the 82 patients treated with antihy-
pertensive medications (78 for HTN and 4 for break-
through HTN), 74 patients continued therapy, 4
discontinued therapy and remained hypertensive, and
4 discontinued therapy and were normotensive (2 had
achieved weight loss). Among the 74 patients remain-
ing on therapy, 43 had achieved adequate blood pres-
sure control of \140/90 mmHg in nondiabetic
patients and\130/80 mmHg in diabetic patients, 17
were not adequately controlled, and 14 were not evalu-
able. Among the 38 untreated patients, 27 continued to
be hypertensive, 8 became normotensive (5 had
achieved weight loss), and 3 were not evaluable. Renal
imagingwas performed in 14 patients at amedian of 4.3
(1.7-11.2) years after the onset ofHTN, of whom 8 had
normal renal ultrasounds and 6 had abnormalities,
including renal artery stenosis (n 5 2), renal cysts
(n52), small kidneys (n51), andnephrolithiasis (n5 1).
Among the 120 patients, 3 developed end-stage renal
disease (2 received kidney transplants and 1 was on di-
alysis). Four patients developed congestive heart failure
and 4 had strokes. Sixteen patients died, but only 1
death was related to HTN after renal transplantation.Risk Factors for HTN
Variables associated with the development of HTN
in multivariate analyses are shown in Table 3. In multi-
variate analysis, the strongest baseline predictors of
HTN incidence were AKI and TBI. TBI fractionation
was considered, but did not improve the model. HCV
infection was associated with a decreased risk of HTN.
Autologous and unrelated donors were more likely to
developHTN.Among time-dependent factors, obesity,
diabetes, and growth hormone therapy were associated
with an increased risk of HTN. The cumulative inci-
dences of HTN by transplant diagnosis, AKI, and TBI
are shown in Figures 1 to 3. The 20-year cumulative in-
cidence ofHTNwasALL22%,AML14%,CML28%,
MDS 26%, AA 9%, neuroblastoma 31%, and primary
immunodeficiencies and red blood cell disorders 3%.
The 30-year cumulative incidence of HTN was ALL
44%, AML 29%, and AA 26%.
Table 2. Characteristics of Hypertensive Patients at Onset of Hypertension (n 5 120)
Total
Children
(age <18 years)
Adults
(age $18 years)
Number of patients 120 34 86
Age post-HCT at onset—years 25 (3-46) 13 (3-17) 30 (18-46)
Time post-HCT at onset—years 14 (1-32) 7 (1-14) 18 (2-32)
Hypertension
Evaluable (unknown) 105 (15) 32 (2) 73 (13)
Isolated systolic 31 (30%) 13 (41%) 18 (25%)
Isolated diastolic 26 (25%) 4 (13%) 22 (30%)
Systolic and diastolic 48 (46%) 15 (47%) 33 (45%)
Estimated GFR at onset
Evaluable (unknown) 72 (48) 25 (9) 47 (39)
Low (GFR <90) 23 (32%) 2 (8%) 21 (45%)
Normal (GFR $90) 49 23 26
Renal Imaging
Performed (abnormal) 10 7 3
Abnormal 2 (20%) 1 (14%) 1 (33%)
Medications at onset
Growth hormone 13 13 –
Thyroid 25 7 18
Sex hormone 30 8 22
Antidepressant 16 3 13
Body mass index*
Normal or underweight 66 20 46
At-risk or overweight 34 8 26
Obese 20 (17%) 6 (18%) 14 (16%)
Mean (range) – 64% (1%-98%) 25.3 (10.4-46.3)
Diabetes 19 (16%) 1 (3%) 18 (21%)
Hepatitis C infection
(Yes : No : Unknown) 24 : 71 : 25 0 : 28 : 6 24 : 43 : 19
Smoker (Yes : No : Unknown) 15 : 103 : 2 3 : 31 : 0 12 : 72 : 2
GFR indicates glomerular filtration rate (mL/min/1.73 m2); HCT, hematopoietic cell transplantation.
*Body mass index (BMI): in children <18 years old, using BMI for age and-sex percentiles, categories defined as normal/underweight <85%, at-risk 85% to
95%, and obese $95%. In adults, using BMI, categories defined as normal/underweight <25, overweight 25 to 30, and obese $30.
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At the time of analysis, 612 of the 689 patients in
the study were alive including 104 of the 120 patients
who developed HTN. Eleven of the 104 patients
who developed HTN became normotensive and
were not included in the prevalence calculation.Table 3. Multivariate Analysis of Risk Factors for the
Development of Hypertension
Risk factor Hazard ratio 95% CI P-value
Acute kidney injury <.0001
Yes 2.53 (1.7-3.7)
No 1.0 –
Total body irradiation* .001
Yes 2.06 (1.3-3.3)
No 1.0 –
Hepatitis C virus infection .009
Yes 0.52 (0.3-0.9)
Unknown 0.55 (0.3-0.9)
No 1.0 –
Donor type .01
Autologous 2.39 (1.3-4.4)
Unrelated 1.79 (1.0-3.2)
Related 1.0 –
Obesity 3.98 (2.3-6.8) <.0001
Diabetes 6.59 (3.9-11.0) <.0001
Growth hormone therapy 1.58 (1.0-2.5) .05
CI indiates confidence interval.
*Total body irradiation (TBI) included single fraction (10 Gy) and frac-
tionated (12-15.75 Gy). Low-dose TBI (2-6 Gy) was included in the
No-TBI category.Thus, the overall prevalence of HTN among surviving
patients was 15% (93/612). The prevalence increased
with age from 7% among\11 year olds, 10% for 11
to 17 year olds, 13% for 18 to 39 year olds, and 31%
for 40 to 59 (mean, 44 years old) year olds. The prev-
alence increased with time after transplantation from
7% at 5 to 9 years post-HCT, 12% at 10 to 19 years,
17% at 20 to 29 years, and 36% at $30 years. The
prevalence of HTN was higher in obese (33%) versus
nonobese (5%) children and higher in obese (26%)
versus nonobese (15%) adults. HTN was also more
prevalent in patients with diabetes than without
(52% versus 11%).
Table 4 presents the prevalence of HTN by se-
lected diagnosis at transplant. Among other diagnoses
not shown in Table 4, the prevalence of HTN was
20% (3/15) NHL, 20% (1/5) brain tumors, 17%
(1/6) juvenile myelomonocytic leukemia, 13% (5/39)
neuroblastoma, 13% (1/8) Hodgkin disease (HD),
10% (1/10) Fanconi’s anemia, and 6% (1/18) primary
immunodeficiencies. There were no cases of HTN
among 25 patients diagnosed with rare diseases.DISCUSSION
This is the first study to report the prevalence of
hypertension in a large population of pediatric HCT
Figure 1. Cumulative incidence of hypertension by selected diagnoses
at transplant.
Figure 3. Cumulative incidence of hypertension by total body irradia-
tion, P-value 5 .0003.
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survivors with up to 36 years of follow-up. These pa-
tients developed HTN at an average age of 25 years
old, earlier than the general population that typically
develops HTN after 40 years of age [5]. The early on-
set of HTN appears to be multifactorial, resulting
from both multiple risk factors at the time of trans-
plantation and the development of diabetes and obe-
sity after transplantation.
HTN developed in 17% of our patients, which is
higher than the 0%-12% incidence previously re-
ported in pediatric HCT studies [1-4], which may be
because of differences in TBI dose, donor types, and
length of follow-up. The majority (87%) of patients
in the present study received allogeneic transplants
and the median length of follow-up was 16 years com-
pared to 5 to 10 years in the prior studies. Kist-van
Holthe et al. [4] observed no HTN among patients
treated with TBI given as 4 to 8 Gy in 1 fraction or
12 Gy in 2 fractions, whereas in our study TBI wasFigure 2. Cumulative incidence of hypertension by development of
acute kidney injury (defined as a doubling of baseline serum creatinine
by day 100 after transplantation), p-value\.0001.generally given at 10 Gy in a single fraction or 12 to
15.75 Gy in 6 to 7 fractions.
The prevalence of HTN was higher in our patient
population than in the general U.S. population [5,46].
In the United States, the prevalence of HTN among
children aged 11 to 17 years of age is estimated to be
3.2% [46]. In the present study, the prevalence of
HTN among patients 11 to 17 years old was 10%, or
3 times higher than expected. In the United States,
the prevalence of HTN, based on the National Health
and Nutrition Examination Survey 2003 to 2004
survey, was estimated to be 7.3% among 18-to 39-
year-olds and 32.6% among 40- to 59-year-olds [5].
Among survivors 18 to 39 years of age, the prevalence
of HTNwas 13% or 2 times higher than expected, but
not different among survivors 40 to 59 years old (31%).
One possible explanation for this finding is because of
the fact that survivors were relatively younger at
a mean age of 44 years, compared to an expected
mean age of 50 years among 40- to 59-year-olds in
the general population. In calculating prevalence, we
exclude patients who developed HTN, but had be-
come normotensive by nonpharmacological means,
such as weight loss. Given the retrospective design of
this study, it is possible that HTN may be either
underdiagnosed or underreported. Hence, the present
study confirms that HTN is a prevalent late effect of
pediatric HCT and the true prevalence may be higher
than presently reported.
In multivariate analysis, the most significant base-
line risk factor identified for the development of HTN
was AKI, suggesting that renal damage plays a role in
the pathophysiology of HTN. Identified risk factors
for AKI include SOS, amphotericin use, younger age
(\5 years) and older age (.25 years), jaundice, weight
gain, donor type, and a high pre-HCT serum creati-
nine [3,9-12,47]. TBI has not been associated with
AKI, except in a study by Frisk et al. [3]. In the present
study, AKI occurred in 34% of patients, which is
Table 4. Prevalence of Hypertension by Selected Diagnosis and Risk Factors
ALL AML CML MDS AA
% (Cases / Survivors) % (Cases / Survivors) % (Cases / Survivors) % (Cases / Survivors) % (Cases / Survivors)
Total patients 20% (32 / 162) 12% (17 / 145) 17% (9 / 52) 20% (6 / 30) 17% (16 / 97)
Preparative regimen
Total body irradiation based 20% (32 / 161) 15% (14 / 94) 20% (9 / 46) 26% (5 / 19) 8% (1 / 12)
Cy – – – – 21% (15 / 71)
Bu/Cy – 6% (2 / 36) 0% (0 / 3) 11% (1 / 9) –
Two transplants 0% (0 / 1) 7% (1 / 15) 0% (0 / 3) 0% (0 / 2) 0% (0 / 11)
Survival period
30 years or more 70% (7 / 10) 38% (3 / 8) – – 24% (9 / 37)
20-30 years 18% (11 / 61) 15% (10 / 67) 32% (6 / 19) 40% (2 / 5) 9% (3 / 32)
10-20 years 18% (12 / 67) 4% (2 / 56) 11% (3 / 27) 19% (4 / 21) 18% (4 / 22)
5-10 years 8% (2 / 24) 14% (2 / 14) 0% (0 / 6) 0% (0 / 4) 0% (0 / 6)
Mean (range) years 19.0 (5.5 – 34.5) 20.3 (5.6 – 37.0) 18.0 (6.1 – 28.0) 16.7 (6.2 – 27.3) 25.0 (5.5 – 37.0)
Age at analysis
40-59 years 19% (4 / 21) 36% (9 / 25) 0% (0 / 2) 100% (1 / 1) 31% (11 / 35)
18-39 years 22% (24 / 111) 7% (8 / 110) 18% (9 / 49) 17% (4 / 23) 9% (5 / 59)
11-17 years 13% (3 / 24) 0% (0 / 7) 0% (0/ 1) 20% (1 / 5) 0% (0 / 2)
<11 years 17% (1 / 6) 0% (0 / 3) – 0% (0 / 1) 0% (0 / 1)
Diabetes
Yes 64% (14 / 22) 36% (9 / 25) 57% (4/ 7) 100% (2 / 2) 71% (5 / 7)
No 13% (18 / 140) 7% (8 / 120) 11% (5 / 45) 14% (4 / 28) 12% (11 / 90)
Body mass index*
Child–not obese (<95th) 8% (2 / 24) 0% (0 / 9) 0% (0 / 1) 17% (1 / 6) 0% (0 / 1)
Child–obese ($95th) 40% (2 / 5) 0% (0 / 1) – – 0% (0 / 2)
Adult not obese (<30) 21% (26 / 123) 11% (14 / 123) 17% (8 / 48) 24% (5 / 21) 13% (9 / 70)
Adult–obese ($30) 20% (2 / 10) 25% (3 / 12) 33% (1 / 3) 0% (0 / 3) 29% (7 / 24)
AA indicates aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; Bu, busulfan; CML, chronic myelogenous leukemia;
CY, cyclophosphamide; HCT, hematopoietic cell transplantation; MDS, myelodysplastic syndrome.
*Body mass index (BMI, kg/m2). Obesity was defined as a BMI$95th percentile based on age and sex in patients <18 years old and a BMI$30 in patients
$18 years old.
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ported by Kist-van Holthe et al. [10] and lower than
the 36% to 53% incidence reported in 2 prior reviews
of Seattle patients (adult and pediatric) undergoing al-
logeneic transplantation in 1986 and 1997 to 2000
[9,11]. Our incidence may also be lower because of
the inclusion of autologous recipients who have a lower
reported incidence of AKI ranging from 2.5% to 6.5%
[3,12].
We hypothesize that AKI may lead to chronic kid-
ney disease and HTN in a subset of patients. In 2 pre-
vious Seattle studies, AKI has been shown to be a risk
factor for chronic kidney disease in myeloablative
(MA) and NMA transplants [48,49]. In the present
study, 32% of evaluable patients had evidence of
chronic kidney disease (GFR\90 mL/min/1.73 m2)
at the onset of HTN, of whom 39% had developed
AKI during HCT. Although HTN is known to be
both a cause and a complication of chronic kidney dis-
ease, the chronic kidney disease in our patients pre-
ceded the development of HTN, thus supporting the
hypothesis that AKI had progressed to chronic kidney
disease and HTN in one-third of our patients. Fur-
thermore, the associated of chronic kidney disease
and HTN has also been observed in a study of adult
HCT patients [50].
The second most significant risk factor for the de-
velopment of HTN was TBI. TBI is a recognized risk
factor for radiation nephropathy, chronic kidneydisease, and may increase the risk of diabetes. Radia-
tion nephropathy, also known as ‘‘bone marrow trans-
plantation nephropathy,’’ may occur several months to
years after irradiation and typically presents with
azotemia, HTN, and anemia [13]. Renal shielding
may reduce the incidence of radiation nephropathy,
but none of our patients had renal shielding [51].
TBI has been associated with chronic kidney disease
in several studies, but not all [3,4,52,53]. TBI has
been associated with an increased risk of diabetes
[18]. The present study is the first to find a direct asso-
ciation between TBI and HTN. In a previous study by
Baker et al. [18], TBI was not associated with HTN,
but the patient population included both pediatric
and adult HCT survivors, and the mean follow-up
period was shorter (9 versus 17 years).
The thirdmost significant risk factor for HTNwas
HCV infection status. Patients with HCV infection
had a lower risk of developing HTN than uninfected
patients. The finding that subjects withHCV infection
are less likely to be hypertensive was also observed in
a large study of 171,665 veterans, although the reasons
for this association are not fully understood [54].
The fourth most significant risk factor for the de-
velopment of HTN was donor type. Autologous and
unrelated donor recipients were found to be at higher
risk of developing HTN than related donor recipients.
The higher risk of developing HTN among autolo-
gous recipients contrasts with 2 previous studies that
522 Biol Blood Marrow Transplant 16:515-524, 2010P. A. Hoffmeister et al.found autologous transplantation carries a lower risk
of HTN [3,18]. One possible explanation for this find-
ing is that 40% of autologous recipients in the present
study were transplanted for neuroblastoma, which had
the highest incidence of HTN as shown in Figure 1.
Treatment of neuroblastoma patients may include
nephrectomy, abdominal radiation, and nephrotoxic
platinum compounds, which might predispose them
to developing renal problems. In 1 study, 72% (8/11)
of neuroblastoma patients receiving HCT developed
late renal problems associated with radiation [55].
Thus, the inclusion of neuroblastoma patients may ex-
plain the higher risk of autologous patients developing
HTN than related donor recipients. However, it is un-
clear why unrelated donor recipients would have
a higher risk of developing HTN than related donors.
Although unrelated and related donor recipients dif-
fered in both the composition of diseases leading to
HCT and the incidence of developing cGVHD, nei-
ther diagnosis at transplant, cGVHD, type of immu-
nosuppression, nor duration of cGVHD therapy
were associated with HTN in multivariate analysis.
Thus, the lack of an association between HTN and
cGVHD or immunosuppressive therapies suggests
that some other characteristic of unrelated donor
transplants predisposes patients to HTN.
Other significant risk factors for the development of
HTN in multivariate analysis were time-dependent
variables, including obesity, diabetes, and growth hor-
mone usage. Obesity and diabetes are well-established
risk factors for HTN. In the present study, 17% of
patients were obese and 16% were diabetic when they
developed HTN. We have previously reported an
increased risk of type 2 diabetes in our patient popula-
tion [17]. Taken together, HTN, diabetes, and obesity
suggest the possibility that the etiology of HTN in
someof our patientsmay be a result of havingdeveloped
themetabolic syndrome, defined as the clustering of ad-
verse metabolic conditions (hypertension, insulin resis-
tance, dyslipidemia, and obesity.) Pediatric HCT
survivors appear to be at risk for developing the meta-
bolic syndrome [14-16]. Additionally, diabetes andobe-
sity can worsen underlying chronic kidney disease,
thereby accelerating the development of HTN. Last,
growth hormone therapy was marginally associated
with an increased risk ofHTN(P5 .05).These patients
had received growth hormone therapy for a median of
2.7 (1.7-4.7) years prior to developing HTN. We are
not aware of an increased risk of HTN associated
with growth hormone therapy. However, growth hor-
mone deficiency has been associated with a higher risk
of developing of developing features of the metabolic
syndrome in adult survivors of childhood leukemia [56].
HTN represents a significant health risk for pedi-
atric HCT survivors. HTN is an important risk factor
for a variety of serious diseases and conditions, includ-
ing heart disease (ischemic heart disease and heartfailure), stroke, chronic kidney disease, peripheral
artery disease, retinopathy, and dementia [38]. The
Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of
Hypertension [38], defined control of adult blood
pressure as a systolic pressures\140 mmHg and dia-
stolic pressures\90 mmHg and\130/80 mmHg in
diabetic patients. In the present study, 72% of treated
patients achieved adequate blood pressure control, but
27 hypertensive patients were untreated. Unfortu-
nately, 3 patients developed end stage renal disease, 4
developed congestive heart failure, 4 had strokes, and
1 patient died of HTN related complications.
Screening for HTN is recommended for long-
term survivors of HCT. Current guidelines suggest
that blood pressure should be checked at least every
2 years [8]. Although determining the optimal screen-
ing interval was beyond the scope of the present study,
the high prevalence of HTN in the present study sug-
gests the need for more frequent screening. In screen-
ing patients, it is noteworthy to mention that at onset
of HTN, 41% of children and 25% of adults had iso-
lated systolic HTN (ISH), whereas in the general pop-
ulation, ISH occurs in roughly 18% of untreated
hypertensive adults less than 40 years of age [57]. Cur-
rent guidelines also recommend a trial of nonpharma-
cologic treatments for mild hypertension and include
moderate dietary sodium restriction, weight reduction
in the obese, avoidance of excess alcohol intake, and
regular aerobic exercise [8]. Twelve patients success-
fully became normotensive with nonpharmacologic
treatments. However, given the association between
HTN and chronic kidney disease, early treatment
and referral to a nephrologist may be indicated.
The major limitation of our retrospective study
was that the identification of hypertensive cases was
dependent on the availability of follow-up records
and patient access to medical care; therefore, the prev-
alence of HTN may be underestimated. We were also
limited in our ability to assess certain potential risk fac-
tors including excess alcohol consumption, diet, phys-
ical inactivity, and cumulative steroid exposure, which
has been significantly associated with hypertension in
non-HCT ALL patients [58]. Last, assessing associa-
tions between HTN and hypercholesterolemia and
the metabolic syndrome were beyond the scope of
the present study.CONCLUSION
Survivors of pediatric HCT appear more likely to
develop HTN than the general population. HTN typ-
ically occurred in nonobese, adolescent, and young
adult HCT survivors. Risk factors for the development
of HTN included AKI, TBI, negative history of HCV
infection, autologous (primarily neuroblastoma
Biol Blood Marrow Transplant 16:515-524, 2010 523Hypertension after pediatric HCTpatients) and unrelated donor types, obesity, and dia-
betes. At-risk patients should be educated and moni-
tored for the development of HTN. Medical
providers should screen patients and refer cases to a ne-
phrologist for specialized care. Research to further un-
derstand the etiology and pathogenesis of HTN in
transplant patients is needed.ACKNOWLEDGMENTS
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